Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

473 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panés J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass A; QUASAR Study Group. Peyrin-Biroulet L, et al. Among authors: panes j. Gastroenterology. 2023 Dec;165(6):1443-1457. doi: 10.1053/j.gastro.2023.08.038. Epub 2023 Sep 1. Gastroenterology. 2023. PMID: 37659673 Free article. Clinical Trial.
A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease.
Reinisch W, Panés J, Lémann M, Schreiber S, Feagan B, Schmidt S, Sturniolo GC, Mikhailova T, Alexeeva O, Sanna L, Haas T, Korom S, Mayer H. Reinisch W, et al. Among authors: panes j. Am J Gastroenterol. 2008 Sep;103(9):2284-92. doi: 10.1111/j.1572-0241.2008.02024.x. Epub 2008 Jul 30. Am J Gastroenterol. 2008. PMID: 18671816 Clinical Trial.
Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data.
Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Schölmerich J, Panés J, Sandborn WJ; PRECiSE 2 Study Investigators. Schreiber S, et al. Among authors: panes j. Am J Gastroenterol. 2010 Jul;105(7):1574-82. doi: 10.1038/ajg.2010.78. Epub 2010 Mar 16. Am J Gastroenterol. 2010. PMID: 20234346 Clinical Trial.
Development of the Crohn's disease digestive damage score, the Lémann score.
Pariente B, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, Chowers Y, D'Haens G, Feagan BG, Hibi T, Hommes DW, Irvine EJ, Kamm MA, Loftus EV Jr, Louis E, Michetti P, Munkholm P, Oresland T, Panés J, Peyrin-Biroulet L, Reinisch W, Sands BE, Schoelmerich J, Schreiber S, Tilg H, Travis S, van Assche G, Vecchi M, Mary JY, Colombel JF, Lémann M. Pariente B, et al. Among authors: panes j. Inflamm Bowel Dis. 2011 Jun;17(6):1415-22. doi: 10.1002/ibd.21506. Epub 2010 Nov 28. Inflamm Bowel Dis. 2011. PMID: 21560202 Free PMC article.
The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.
Van Assche G, Lewis JD, Lichtenstein GR, Loftus EV, Ouyang Q, Panes J, Siegel CA, Sandborn WJ, Travis SP, Colombel JF. Van Assche G, et al. Among authors: panes j. Am J Gastroenterol. 2011 Sep;106(9):1594-602; quiz 1593, 1603. doi: 10.1038/ajg.2011.211. Epub 2011 Aug 16. Am J Gastroenterol. 2011. PMID: 21844919 Review.
Rituximab in active ulcerative colitis.
Calderón-Gómez E, Panés J. Calderón-Gómez E, et al. Among authors: panes j. Gastroenterology. 2012 Jan;142(1):174-6. doi: 10.1053/j.gastro.2011.11.009. Epub 2011 Nov 21. Gastroenterology. 2012. PMID: 22115625 No abstract available.
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Niezychowski W; Study A3921063 Investigators. Sandborn WJ, et al. Among authors: panes j. N Engl J Med. 2012 Aug 16;367(7):616-24. doi: 10.1056/NEJMoa1112168. N Engl J Med. 2012. PMID: 22894574 Free article. Clinical Trial.
473 results